Terms: = Prostate cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Prognosis
12 results:
1. Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
Cattrini C; Manfredi M; Barboro P; Ghirimoldi M; Mennitto A; Martini V; Battioni A; Le Van M; Gobbato S; Branni C; Ayed RB; Pinato DJ; Catalano F; Zanardi E; Boccardo F; Gennari A
Sci Rep; 2023 Oct; 13(1):17791. PubMed ID: 37853018
[TBL] [Abstract] [Full Text] [Related]
2. C reactive protein/Albumin ratio as predictor of prognosis in castration resistant metastatic prostate cancer.
Lorigo J; Tavares Silva E; Pedroso Lima J; Quaresma V; Pedrosa R; Figueiredo A
Arch Ital Urol Androl; 2023 Jul; 95(3):11242. PubMed ID: 37435750
[TBL] [Abstract] [Full Text] [Related]
3. prostate cancer Immunotherapy-Finally in From the Cold?
Runcie KD; Dallos MC
Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
[TBL] [Abstract] [Full Text] [Related]
4. Development and Validation of a Prognostic Survival Model With Patient-Reported Outcomes for Patients With cancer.
Seow H; Tanuseputro P; Barbera L; Earle C; Guthrie D; Isenberg S; Juergens R; Myers J; Brouwers M; Sutradhar R
JAMA Netw Open; 2020 Apr; 3(4):e201768. PubMed ID: 32236529
[TBL] [Abstract] [Full Text] [Related]
5. The use of
Raveenthiran S; Yaxley J; Gianduzzo T; Kua B; McEwan L; Wong D; Tsang G; MacKean J
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):385-390. PubMed ID: 31363165
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy and safety of chimeric antigen receptor T-cell (car-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract] [Full Text] [Related]
7. The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies.
Slovin SF
Biomark Med; 2017 Dec; 11(12):1149-1159. PubMed ID: 29186979
[TBL] [Abstract] [Full Text] [Related]
8. The demographic features, clinical outcomes, prognosis and treatment options for patients with sarcomatoid carcinoma of the urinary bladder: a single centre experience.
Robinson SP; Farooq A; Laniado M; Motiwala H
Int Braz J Urol; 2018; 44(1):45-52. PubMed ID: 29064650
[TBL] [Abstract] [Full Text] [Related]
9. Addressing issues associated with evaluating prediction models for survival endpoints based on the concordance statistic.
Wang M; Long Q
Biometrics; 2016 Sep; 72(3):897-906. PubMed ID: 26756274
[TBL] [Abstract] [Full Text] [Related]
10. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters.
Chen Y; Tang Y; Guo C; Wang J; Boral D; Nie D
Biochem Pharmacol; 2012 Apr; 83(8):1112-26. PubMed ID: 22326308
[TBL] [Abstract] [Full Text] [Related]
11. [carcinoma-associated retinopathy: a review with clinical examples].
Sobottka B; Schlote T; Besch D; Djelebova T; Wilhelm H; Zrenner E
Klin Monbl Augenheilkd; 2000 Jan; 216(1):17-24. PubMed ID: 10702938
[TBL] [Abstract] [Full Text] [Related]
12. [Laparoscopic lymphadenectomy for lymphatic staging in prostatic cancer: preliminary experience].
Rioja Sanz C; Mínguez Pemán JM; Blas Marín M; Martínez Bengoechea J; Rioja Sanz LA
Actas Urol Esp; 1991; 15(6):515-7. PubMed ID: 1838894
[TBL] [Abstract] [Full Text] [Related]
